We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Prototype Kit Diagnoses Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 07 May 2013
A prototype direct agglutination test (DAT) kit for the laboratory diagnosis of visceral leishmaniasis (VL), called DAT-LPC, has been developed. More...


The diagnosis validity of this prototype DAT-LPC, which uses a freeze-dried antigen, was performed to evaluate the sensitivity and specificity of the assay.

Scientists at the Oswaldo Cruz Foundation (FIOCRUZ; Belo Horizonte, Brazil) took blood samples from 103 Brazilian patients with VL and 110 samples from patients with other parasitic infections, and healthy subjects. These samples were assayed with DAT-LPC and DAT-KIT (Royal Tropical Institute; Amsterdam, NL). Additionally, the results of 103 samples of VL patients based on two agglutination tests were correlated.

The DAT-LPC was incubated for four hours at room temperature; the end titer was read as the dilution immediately before the well with a clear sharp-edged blue spot identical in size to the reaction negative control. Appropriate negative and positive control samples with known DAT titers were included. The cut-off for interpretation of positive and negative results was 1:100. The DAT-LPC showed a sensitivity of 99.0%, specificity of 98.2% and diagnosis validity of 98.6%, which were similar to those found by the DAT-KIT. Moreover, there was positive correlation between the positive titers obtained by DAT-LPC and by DAT-KIT.

After six months of storage in an incubator at 40 °C and 75% moisture the DAT-LPC prototype remained stable. Physical aspects remained the same, and it produced consistent results with negative and positive samples assayed monthly. The authors concluded that the prototype kit showed high diagnostic accuracy and thermal stability; it is ready for use and could be transferred to industrial production. The DAT-LPC should replace the indirect immunofluorescent antibody test (IFAT) in routine serological tests for VL diagnosis in Brazil. It could be used in a complementary algorithm with immunochromatic dipstick tests, for different clinical scenarios and laboratorial settings. The study was published on February 3, 2013, in the journal Transactions of The Royal Society of Tropical Medicine and Hygiene.

Related Links:

Oswaldo Cruz Foundation
Royal Tropical Institute



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.